Crizotinib in ROS1-rearranged non-small-cell lung cancer

New England Journal of Medicine

Volumn 371, Issue 21, 2014, Pages 1963-1971

  Shaw, Alice T ^a   Ou, Sai Hong I ^d   Bang, Yung Jue ^f   Camidge, D Ross ^g   Solomon, Benjamin J ^h   Salgia, Ravi ⁱ   Riely, Gregory J ^j   Varella Garcia, Marileila ^g   Shapiro, Geoffrey I ^b   Costa, Daniel B ^c   Doebele, Robert C ^g   Le, Long Phi ^a   Zheng, Zongli ^a,k   Tan, Weiwei ^e   Stephenson, Patricia ^l   Shreeve, S Martin ^e   Tye, Lesley M ^e   Christensen, James G ^e   Wilner, Keith D ^e   Clark, Jeffrey W ^a   Iafrate, A John ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e PFIZER INC   (United States)

^f Seoul National University Hospital   (South Korea)

^g UNIVERSITY OF COLORADO   (United States)

^h PETER MACCALLUM CANCER CENTRE   (Australia)

ⁱ UNIVERSITY OF CHICAGO   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^k KAROLINSKA INSTITUTE   (Sweden)

^l Rho   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN;

ADULT; AGED; ALK GENE; ARTICLE; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; FATIGUE; FEMALE; FUSION GENE; GENE; HUMAN; HYPOPHOSPHATEMIA; MALE; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; ROS1 GENE; SINUS BRADYCARDIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT; VOMITING; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICALLY INDUCED; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; VISUAL DISORDER;

ADMINISTRATION, ORAL; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; TREATMENT OUTCOME; VISION DISORDERS;

EID: 84911372597     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1406766     Document Type: Article

References (34)

1. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009;1795:37-52.
2. Birchmeier C, Birnbaum D, Waitches G, Fasano O, Wigler M. Characterization of an activated human ros gene. Mol Cell Biol 1986;6:3109-16.
3. Nagarajan L, Louie E, Tsujimoto Y, Balduzzi PC, Huebner K, Croce CM. The human c-ros gene (ROS) is located at chromosome region 6q16→6q22. Proc Natl Acad Sci U S A 1986;83:6568-72.
4. Matsushime H, Wang LH, Shibuya M. Human c-ros-1 gene homologous to the v-ros sequence of UR2 sarcoma virus encodes for a transmembrane receptorlike molecule. Mol Cell Biol 1986;6:3000-4.
5. Charest A, Lane K, McMahon K, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003;37:58-71.
6. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203.
7. Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6(1):e15640.
8. Lee J, Lee SE, Kang SY, et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 2013;119:1627-35.
9. Birch AH, Arcand SL, Oros KK, et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One 2011;6(12):e28250.
10. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013;19:4040-5.
11. Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist 2013;18:865-75.
12. Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
13. Huber KV, Salah E, Radic B, et al. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature 2014;508:222-7.
14. Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 rearrangement. Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, June 1-5, 2012. abstract.
15. McDermott U, Iafrate AJ, Gray NS, et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008;68:3389-95.
16. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Preclinical rationale for use of the clinically available mul-titargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012;7:1086-90.
17. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-9.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
20. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703. [Erratum, N Engl J Med 2011;364:588.]
21. Kwak EL, Camidge DR, Clark JW, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-MET and ALK inhibitor, PF-02341066. J Clin Oncol 2009;27:Suppl:148s. abstract.
22. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-9.
23. Zheng Z, Zhelyazkova B, Panditi D, et al. Anchored multiplex PCR for detection of gene rearrangements and mutations using next-generation sequencing. Nat Med (in press).
24. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94.
25. Maul RS, Chang DD. EPLIN, epithelial protein lost in neoplasm. Oncogene 1999;18:7838-41.
26. Lankes WT, Furthmayr H. Moesin: a member of the protein 4.1-talin-ezrin family of proteins. Proc Natl Acad Sci U S A 1991;88:8297-301.
27. Awad MM, Katayama R, McTigue M, et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013;368:2395-401.
28. Huang Q, Johnson TW, Bailey S, et al. Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib. J Med Chem 2014;57:1170-87.
29. Yoshida A, Kohno T, Tsuta K, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013;37:554-62.
30. Davies KD, Mahale S, Astling DP, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 2013;8(12):e82236.
31. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97.
32. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
33. Gettinger SN, Bazhenova L, Salgia R, et al. Updated efficacy and safety of the ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC). Presented at the Annual Meeting of the American Society of Clinical Oncology, Chicago, May 30-June 3, 2014. abstract.
34. Marsilje TH, Pei W, Chen B, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2- (isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013;56:5675-90.